43 related articles for article (PubMed ID: 15308567)
1. Recipient leukocyte infusion enhances the local and systemic graft-versus-neuroblastoma effect of allogeneic bone marrow transplantation in mice.
Willems L; Fevery S; Sprangers B; Rutgeerts O; Lenaerts C; Ibrahimi A; Gijsbers R; Van Gool S; Waer M; Billiau AD
Cancer Immunol Immunother; 2013 Nov; 62(11):1733-44. PubMed ID: 24081484
[TBL] [Abstract][Full Text] [Related]
2. Characterization of effector cells of graft vs leukemia following allogeneic bone marrow transplantation in mice inoculated with murine B-cell leukemia.
Weiss L; Weigensberg M; Morecki S; Bar S; Cobbold S; Waldmann H; Slavin S
Cancer Immunol Immunother; 1990; 31(4):236-42. PubMed ID: 2379219
[TBL] [Abstract][Full Text] [Related]
3. Age-related defects in B lymphopoiesis underlie the myeloid dominance of adult leukemia.
Signer RA; Montecino-Rodriguez E; Witte ON; McLaughlin J; Dorshkind K
Blood; 2007 Sep; 110(6):1831-9. PubMed ID: 17554060
[TBL] [Abstract][Full Text] [Related]
4. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia.
Marijt WA; Heemskerk MH; Kloosterboer FM; Goulmy E; Kester MG; van der Hoorn MA; van Luxemburg-Heys SA; Hoogeboom M; Mutis T; Drijfhout JW; van Rood JJ; Willemze R; Falkenburg JH
Proc Natl Acad Sci U S A; 2003 Mar; 100(5):2742-7. PubMed ID: 12601144
[TBL] [Abstract][Full Text] [Related]
5. Suppression of E-protein activity interferes with the development of BCR-ABL-mediated myeloproliferative disease.
Ko J; Patel N; Ikawa T; Kawamoto H; Frank O; Rivera RR; Van Etten RA; Murre C
Proc Natl Acad Sci U S A; 2008 Sep; 105(35):12967-72. PubMed ID: 18725623
[TBL] [Abstract][Full Text] [Related]
6. Differential gene expression in acute lymphoblastic leukemia cells surviving allogeneic transplant.
Shand JC; Jansson J; Hsu YC; Campbell A; Mullen CA
Cancer Immunol Immunother; 2010 Nov; 59(11):1633-44. PubMed ID: 20602231
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes of patients with lymphoid blastic phase of chronic myeloid leukemia treated with CAR T-cell therapy.
Liu Y; Tu Y; Xiao J; Shen Y; Zhou B; Yang Q; Yu L; Qi L; Chen J; Liu T; Wu D; Xu Y
Blood Cancer J; 2024 Mar; 14(1):39. PubMed ID: 38448401
[No Abstract] [Full Text] [Related]
8. Coordinated Immune Cell Networks in the Bone Marrow Microenvironment Define the Graft versus Leukemia Response with Adoptive Cellular Therapy.
Maurer K; Park CY; Mani S; Borji M; Penter L; Jin Y; Zhang JY; Shin C; Brenner JR; Southard J; Krishna S; Lu W; Lyu H; Abbondanza D; Mangum C; Olsen LR; Neuberg DS; Bachireddy P; Farhi SL; Li S; Livak KJ; Ritz J; Soiffer RJ; Wu CJ; Azizi E
bioRxiv; 2024 Feb; ():. PubMed ID: 38405900
[TBL] [Abstract][Full Text] [Related]
9. Complete remission of cancer in late-stage disease by radiation and transfer of allogeneic MHC-matched immune T cells: lessons from GvL studies in animals.
Schirrmacher V
Cancer Immunol Immunother; 2014 Jun; 63(6):535-43. PubMed ID: 24610041
[TBL] [Abstract][Full Text] [Related]
10. Insights into the pathophysiology and therapy of myeloproliferative neoplasms from mouse models.
Van Etten RA
Leuk Suppl; 2014 Dec; 3(Suppl 1):S27-8. PubMed ID: 27175270
[No Abstract] [Full Text] [Related]
11. Visualization of immune response kinetics in full allogeneic chimeras.
Elkin G; Prigozhina TB; Slavin S; Gurevitch O; Khitrin S; Resnick IB
Am J Blood Res; 2011; 1(2):110-8. PubMed ID: 22432073
[TBL] [Abstract][Full Text] [Related]
12. Nonhematopoietic antigen blocks memory programming of alloreactive CD8+ T cells and drives their eventual exhaustion in mouse models of bone marrow transplantation.
Flutter B; Edwards N; Fallah-Arani F; Henderson S; Chai JG; Sivakumaran S; Ghorashian S; Bennett CL; Freeman GJ; Sykes M; Chakraverty R
J Clin Invest; 2010 Nov; 120(11):3855-68. PubMed ID: 20978352
[TBL] [Abstract][Full Text] [Related]
13. ICSBP-mediated immune protection against BCR-ABL-induced leukemia requires the CCL6 and CCL9 chemokines.
Nardi V; Naveiras O; Azam M; Daley GQ
Blood; 2009 Apr; 113(16):3813-20. PubMed ID: 19171873
[TBL] [Abstract][Full Text] [Related]
14. Adoptive immunotherapy of BCR-ABL-induced chronic myeloid leukemia-like myeloproliferative disease in a murine model.
Krause DS; Van Etten RA
Blood; 2004 Dec; 104(13):4236-44. PubMed ID: 15308567
[TBL] [Abstract][Full Text] [Related]
15. Distinct graft-versus-leukemic stem cell effects of early or delayed donor leukocyte infusions in a mouse chronic myeloid leukemia model.
Lu YF; Gavrilescu LC; Betancur M; Lazarides K; Klingemann H; Van Etten RA
Blood; 2012 Jan; 119(1):273-84. PubMed ID: 22072555
[TBL] [Abstract][Full Text] [Related]
16. Kinetics of the graft-versus-leukemia response after donor leukocyte infusions for relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation.
Baurmann H; Nagel S; Binder T; Neubauer A; Siegert W; Huhn D
Blood; 1998 Nov; 92(10):3582-90. PubMed ID: 9808551
[TBL] [Abstract][Full Text] [Related]
17. Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T-cell-depleted allogeneic marrow transplantation for chronic myelogenous leukemia.
Hessner MJ; Endean DJ; Casper JT; Horowitz MM; Keever-Taylor CA; Roth M; Flomenberg N; Drobyski WR
Blood; 1995 Nov; 86(10):3987-96. PubMed ID: 7579370
[TBL] [Abstract][Full Text] [Related]
18. Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation.
Román J; Alvarez MA; Torres A
Haematologica; 2000 Oct; 85(10):1072-82. PubMed ID: 11025600
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
